Literature DB >> 6685507

Vascular effects of piretanide. Studies on extrarenal action in several animal models.

E Klaus, H G Alpermann, G Caspritz, W Linz, B Schölkens.   

Abstract

4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoyl benzoic acid (piretanide, Arelix) was studied for its vasoactive effects in several experimental models. In rat and rabbit thoracic aorta strips, piretanide dose-dependently attenuated contractions induced by norepinephrine (noradrenaline). When contractions were induced by KCl no concentration response curve could be established. Piretanide inhibited the vasoconstrictor response to norepinephrine and to KCl in the rat mesenteric vascular bed. IC50's of 0.5 mmol/l and 4.9 mmol/l, resp., were calculated. In bovine coronary artery strips piretanide caused a marked relaxation. The vasoconstrictor response to PGE2 in piretanide superfused preparations was attenuated in a concentration related manner. Infusion of piretanide (1 mg X ml-1 X min-1) in the isolated guinea pig heart produced a reversible increase of coronary flow. In both normotensive and spontaneously hypertensive bilaterally nephrectomized pithed rats piretanide caused a significant reduction of diastolic blood pressure. The results contribute to the understanding of the antihypertensive effect of piretanide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6685507

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  The absorption of piretanide from the gastro-intestinal tract is site-dependent.

Authors:  D Brockmeier; H G Grigoleit; H Leonhardt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

3.  Vascular effects of loop diuretics: an in vivo and in vitro study in the rat.

Authors:  M Barthelmebs; D Stephan; C Fontaine; M Grima; J L Imbs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

4.  Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: a double-blind comparison with a combination of hydrochlorothiazide and amiloride.

Authors:  M Verho; B Rangoonwala; W Dols
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure--a placebo-controlled trial.

Authors:  W Haerer; U Bauer; N Sultan; K Cernoch; N Mouselimis; K J Fehske; M Hetzel; M Stauch; V Hombach
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

6.  Piretanide, a potassium stable diuretic, in the treatment of essential hypertension.

Authors:  M Verho; B Rangoonwala; W Dols; U Fratzer; J Kaczynski; W Mühlhäusler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Pharmacokinetics of the loop diuretic piretanide in renal failure.

Authors:  U Walter; A Röckel; W Lahn; A Heidland; W Heptner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.